Type I Hypersensitivity Completed Phase 3 Trials for Abrocitinib (DB14973)

Also known as: Immediate Hypersensitivity / Hypersensitivity, Immediate / Immediate Type Hypersensitivity / Immediate hypersensitivity reaction / Immediate hypersensitivity reactions / Allergen-mediated IgE Allergy / Immediate hypersensitivity (disorder) / Hypersensitivity type I / Hypersensitivity type I NOS / Immunoglobulin E-mediated allergic disorder (disorder)

IndicationStatusPhase
DBCOND0030618 (Type I Hypersensitivity)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03720470Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical TherapyTreatment
NCT03627767Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring SubjectsTreatment